NSCLC | Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer

Faculty presentations from a CME symposium held during the ASTRO 2019 Annual Meeting. Featuring perspectives from moderator Dr Corey J Langer and faculty members Drs Shruti Jolly, Billy Wiseman Loo Jr and Jyoti D Patel: Established Management Paradigms and Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Jolly (00:00) Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Langer (10:48) Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-L1 Antibody Therapy for Locally Advanced Disease — Dr Patel (21:44) Ongoing and Planned Clinical Trials of Immune Checkpoint Inhibitors for Patients with Nonmetastatic NSCLC — Dr Loo (36:37) CME information and select publications